SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT. 44th Annual J.P. Morgan Healthcare Conference – Company PresentationDate: Wednes ...

Company Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived ProductsSupply Extension Secures Ongoing Sales of Approximately $5.0-$7.0 Million Per Year for the Period Between Q2-26 and Q1-28Kamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 MillionKamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026 REHOVOT, Israel, an ...

The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination in F4 MASH patients is planned to initiate in 2H 2026 SAN MATEO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive resu ...

LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led by Dr. Janet ...

Core Viewpoint - BioNTech has successfully completed the acquisition of CureVac, enhancing its mRNA technology capabilities and supporting its oncology strategy [1][6]. Group 1: Acquisition Details - The acquisition of CureVac was finalized on December 18, 2025, with the subsequent offering period for CureVac shares expiring at 12:01 a.m. Eastern Time on the same day [1]. - A total of 195,341,219 CureVac shares, representing approximately 86.75% of the outstanding shares, were tendered in the exchange offer [3][6]. - BioNTech plans to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of a post-offer reorganization [3][6]. Group 2: Strategic Implications - The acquisition aims to complement BioNTech's proprietary technologies in mRNA design, delivery formulations, and manufacturing, thereby strengthening its position in the global mRNA industry [1][6]. - BioNTech's oncology strategy focuses on mRNA-based cancer immunotherapy candidates and a bispecific antibody candidate, pumitamig (BNT327/BMS986545), developed in collaboration with Bristol Myers Squibb [1][6]. - The merger is seen as a synergy of two pioneering German mRNA firms, contributing to the country's innovation agenda [2]. Group 3: Management and Operations - Following the acquisition, the Management Board of CureVac SE will consist of BioNTech executives, while former CureVac board members have resigned [2]. - CureVac will continue its existing organizational processes to ensure business continuity, while BioNTech will conduct strategic and operational analyses for future organizational setup [2][6].

Focused on monoclonal antibody therapies for autoimmune diseases, this biotech just reported a significant insider buy in public filings.Immunovant (IMVT +1.39%) spun out of Roivant Sciences Ltd., which reported an open-market purchase of 16,666,666 shares in the biotech company on Dec. 12, 2025, for a total value of ~$350.0 million according to the SEC Form 4 filing.Transaction summaryMetricValueShares traded16,666,666Transaction value$350.0 millionPost-transaction shares (direct)113,317,007Post-transactio ...

Core Points - Hemogenyx Pharmaceuticals plc has issued a total of 123,377 new Ordinary Shares for various reasons, including the exercise of warrants and the vesting of Restricted Stock Units [2][4] - The company raised £190,000 through the exercise of warrants for 105,556 new Ordinary Shares at an exercise price of £1.80 [3] - A total of 6,000 new Ordinary Shares were issued following the vesting of Restricted Stock Units [4] - Additionally, 11,821 new Ordinary Shares were issued under a Deed of Variation at a price of £8.84 per share [5] - The total number of issued shares will reach 6,041,255 upon admission of the new shares, which will be used for shareholder calculations regarding interest notifications [7] - The new shares will be admitted to the FCA official list and trading on the LSE main market, expected around 8:00 a.m. on December 23, 2025 [6] Company Overview - Hemogenyx Pharmaceuticals is a clinical stage biopharmaceutical group focused on developing new medicines and treatments for blood and autoimmune diseases [11] - The company is developing several distinct and complementary product candidates, along with platform technologies for novel product development [11]

Core Viewpoint - InnoCare Pharma has received approval for a Phase II/III clinical trial of its novel TYK2 inhibitor, soficitinib, aimed at treating chronic spontaneous urticaria (CSU), addressing significant unmet medical needs in the dermatology market [1][6]. Group 1: Drug Development - Soficitinib is a selective TYK2 inhibitor being developed for various T-cell related autoimmune disorders, including CSU, atopic dermatitis, and vitiligo [2]. - The drug works by blocking signaling pathways such as IL-4, IL-13, and IL-31, which are involved in mast cell activation and inflammation, thereby reducing symptoms like itch and wheals in CSU patients [3]. Group 2: Market Potential - Chronic spontaneous urticaria affects approximately 50 million patients globally, with the CSU treatment market projected to reach $3 billion by 2029 [5]. - The disease typically lasts two to five years, with some cases extending beyond five years, indicating a substantial need for long-term treatment options [4]. Group 3: Company Overview - InnoCare Pharma is focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases, with a robust pipeline targeting ten major autoimmune diseases [6]. - The company operates in multiple locations, including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States, emphasizing its commitment to addressing unmet medical needs both in China and globally [6].

Core Insights - Absci Corporation is a clinical-stage biopharmaceutical company focused on developing therapeutics using generative AI, participating in the 44th Annual J.P. Morgan Healthcare Conference to showcase its drug discovery advancements [1] Stock Performance - H.C. Wainwright set a price target of $8 for ABSI, indicating a potential increase of about 67.77% from its then-current price of $3.44; the stock is currently priced at $3.39, reflecting a slight decrease of 4.38% [2] - ABSI's stock has shown volatility, with a daily trading range between $3.38 and $3.64; over the past year, it reached a high of $6.33 and a low of $2.01, typical for clinical-stage biopharmaceutical companies [3] Market Position - Absci's market capitalization is approximately $510.4 million, indicating the total market value of its outstanding shares; the trading volume on NASDAQ is 1,986,998 shares, reflecting investor interest [4] - The company's innovative approach in drug discovery, combining AI and synthetic biology, positions it as a notable player in the biopharmaceutical industry [4]

Core Insights - Absci Corporation is a clinical-stage biopharmaceutical company focused on drug discovery using generative AI and synthetic biology [1][5] - The company is participating in the 44th Annual J.P. Morgan Healthcare Conference, indicating its commitment to innovation in therapeutics [4][5] Stock Performance - H.C. Wainwright maintains a "Buy" rating for Absci, raising the price target from $7 to $8, with the stock currently trading at $3.53 [2][5] - The stock has fluctuated between $3.50 and $3.64 during the day, with a yearly high of $6.33 and a low of $2.01 [3][5] - Absci's market capitalization is approximately $531.3 million, with a trading volume of 1,367,859 shares today, indicating active investor interest [3]